



Date: May 19, 2020
To: Alberta Children's Hospital (ACH) Nursing Staff, ACH Physicians, ACH Rapid Response Laboratory (RRL) Staff; APL Clinical Biochemists and General Pathologists
From: Clinical Biochemistry Section, South Sector, Alberta Precision Laboratories (APL)
Re: On-site Troponin I Testing at Alberta Children's Hospital

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message:

- Effective **June 4 2020**, Stat or Time Critical priority troponin orders at Alberta Children's Hospital (ACH) will have **troponin I** tested on-site in addition to **high sensitivity troponin T** tested at Foothills Medical Centre (FMC).
- An additional lavender top EDTA whole blood tube must be collected for the on-site troponin I.

Why this is Important:

- As high-sensitivity troponin T is performed at FMC, approximately 1/3 of Stat/Time Critical troponin orders from ACH have turn-around-times of >120 mins.
- A high-sensitivity system to measure troponin I will be implemented soon; however, in the meantime, a 'normal sensitivity' point of care troponin I at ACH will provide immediate relief to the sections of Pediatric Cardiology, Pediatric Emergency Medicine, Hospital Pediatrics and Pediatric Intensive Care.
- On-site troponin I will provide ACH clinicians with a faster in-term troponin result while awaiting the high-sensitivity troponin result.

Background:

- An elevated troponin I suggests myocardial damage has occurred. However a normal result does not exclude the possibility of myocardial damage. Imprecision of this assay is higher than other troponin assays in the APL-South Sector.

Action Required:

- When ordering troponin as Stat or Time Critical priority, collect an additional lavender top EDTA whole blood tube to have the on-site troponin I test performed.
- For further information, please refer to the APL Test Directory for **Troponin I, (Triage Meter) Alberta Children's Hospital and Viral Hemorrhagic Fever (VHF) – Calgary Zone (CLS)**.

Inquiries and feedback may be directed to:

- Lawrence de Koning, PhD, Clinical Biochemist, Alberta Children's Hospital, South Sector, (403) 955-2277, Lawrence.dekoning@aplabs.ca

This bulletin has been reviewed and approved by:

Hossein Sadrzadeh, PhD, Section Chief, Clinical Biochemistry, South Sector
Leland Baskin, MD, Associate Medical Director, South Sector